(Circulation. 2001;103:670.)
© 2001 American Heart Association, Inc.
Clinical Investigation and Reports |
Differential Activation of Signal Transduction Pathways in Human Hearts With Hypertrophy Versus Advanced Heart Failure
From the Cardiology (S.H., F.d.M., L.G., A.M., R.H., T.F.) and Renal Units (G.C.), Massachusetts General Hospital and Harvard Medical School, Boston, Mass; Division of Molecular Cardiovascular Biology, Children’s Hospital and University of Cincinnati, Cincinnati, Ohio (H.L., K.M.T., J.D.M.); and Boston University School of Medicine, Boston, Mass (J.G.).
Correspondence to Thomas Force, MD, Molecular Cardiology Research Institute, New England Medical Center, Box 8486, 750 Washington St, Boston, MA 02111. E-mail tforce{at}lifespan.org
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background—Left ventricular failure is commonly preceded by a period of hypertrophy. Intriguingly, many of the signaling pathways that have been implicated in the regulation of hypertrophy, including the 3 mitogen-activated protein kinases (MAPKs: extracellular signal-regulated kinase, stress-activated protein kinase, and p38), protein phosphatase, calcineurin, and the protein kinase Akt and its target glycogen synthase kinase-3 (GSK-3), also regulate the apoptotic response.
Methods and Results—To understand the mechanisms that might regulate the progression of heart failure, we analyzed the activity of these signaling pathways in the hearts of patients with advanced heart failure, patients with compensated cardiac hypertrophy, and normal subjects. In patients with hypertrophy, neither the MAPK nor the Akt/GSK-3 pathways were activated, and the dominant signaling pathway was calcineurin. In failing hearts, calcineurin activity was increased but less so than in the hypertrophied hearts, and all 3 MAPKs and Akt were activated (and, accordingly, GSK-3ß was inhibited), irrespective of whether the underlying diagnosis was ischemic or idiopathic cardiomyopathy.
Conclusions—In the failing heart, there is a clear prohypertrophic activity profile, likely occurring in response to increased systolic wall stress and neurohormonal mediators. However, with the activation of these hypertrophic pathways, potent proapoptotic and antiapoptotic signals may also be generated. Therapies directed at altering the balance of activity of these signaling pathways could potentially alter the progression of heart failure.
Key Words: calcineurin • cardiomyopathy • mitogen-activated protein kinases
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
In response to pathological stimuli, the myocardium can undergo adaptive hypertrophic growth to augment cardiac function. Although this response is initially beneficial, sustained cardiac hypertrophy is a leading predicator for the development of heart failure. In recent years, intensive investigation has centered around characterizing intracellular regulatory pathways that are associated with hypertrophy and heart failure in an attempt to design novel pharmacological strategies that may alleviate these responses.
Several intracellular signaling pathways have been implicated in the induction of cardiac hypertrophy. These include the small GTP binding proteins Ras and Rac, the Gq subunit of heterotrimeric G proteins, the 3 main branches of the mitogen-activated protein kinase (MAPK) signaling cascades (extracellular signal-regulated kinases [ERKs], stress-activated protein kinases [SAPKs], and p38s), protein kinase C isoforms, and calcineurin (Cn).1 2 Although these pathways/factors may play important regulatory roles in the development of cardiac hypertrophy in experimental animals, virtually nothing is known about their activation state or regulatory roles in stable, compensated hypertrophy in humans, and little is known about their roles in the failing human heart.
Several reports have examined the associations between intracellular signaling pathways and human heart failure. One showed an association between various protein kinase C isoforms and heart failure.3 More recently, 2 of the MAPK pathways, SAPK and p38 (but not ERK), were reported to be activated in human heart failure due to coronary artery disease (CAD).4 Finally, studies on Cn protein levels in failing human hearts have produced disparate results,5 6 and none have examined Cn activity. Most importantly, all of these reports have focused on individual pathways and, although valuable information has been gained, this approach does not allow for the development of a sense of the relative importance of the various pathways in the progression of disease or their roles at different points in the disease.
Recent evidence suggests that apoptosis may also play an important role in the transition from hypertrophy to heart failure and the progression of failure.7 The serine/threonine kinase protein kinase B (PKB)/Akt pathway transduces antiapoptotic "survival" signals in a number of cells, including cardiomyocytes.8 9 Thus, it is essential to understand the activation state of this kinase to better understand the mechanisms underlying cardiomyocyte apoptosis in the failing heart, but Akt activity in failing (or hypertrophied) human hearts has not been studied.
In the present study, we examined the activity of the following 8 signaling molecules in the hearts of patients with compensated hypertrophy or with advanced heart failure: Cn, SAPK, p38, ERK, Akt, 2 activators of Akt (the insulin-like growth factor-1 [IGF-1] and ErbB2 receptors), and the Akt target glycogen synthase kinase-3 (GSK-3). All of these molecules have been implicated in both hypertrophic and either proapoptotic or antiapoptotic responses.8 10 11 12 13 The activity profiles demonstrate a marked contrast between hearts with compensated hypertrophy and those with advanced failure. These unique profiles of altered regulation in stable hypertrophy versus failure suggest that different molecules could serve as targets for therapies directed at specific phases of the disease.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Western Blotting Procedure
Lysates were matched for protein, separated by SDS-PAGE, and transferred to nitrocellulose membranes, which were probed with the antibodies described below. Antibody binding was detected with chemiluminescence.
The antibodies employed were as follows: anti–c-Jun
NH2-terminal kinase (JNK; recognizing all
SAPK/JNK isoforms), anti-p38, anti-phosphotyrosine (PY20), and
anti-ERK-1/ERK-2 from Santa Cruz Biotechnology; anti-GSK-3ß and
anti-IGF-1 receptor 
subunit (IGF-1R) from Transduction
Laboratories; anti-PKB/Akt from New England Biotechnology; and
anti-ErbB2 from Neomarker. The phospho-specific antibodies we used were
as follows: dual phospho-specific ERK, dual phospho-specific p38,
phospho Ser 473 PKB/Akt, and phospho-STAT3 from New England
Biotechnology and dual phospho-specific SAPK/JNK from
Promega.
To measure total CnA (catalytic subunit) protein content, 2
separate antibodies that recognize either the N-terminus (Chemicon) or
C-terminus (Transduction Laboratories) were used. CnA and Aß
isoform-specific antibodies were also employed (Santa Cruz). Western
blots were processed using enhanced chemiluminescence
(Amersham), and data were quantified with blue fluorescence imaging on
a PhosphorImager. Cn signal intensity was normalized to GAPDH signal.
Protein degradation was monitored with an antibody to protein kinase
C
(Santa Cruz), and 3 samples, 2 failing and 1 normal, were excluded
from analysis.
Immune Complex Kinase Assays
Immune complex kinase assays for ERK-1/-2, SAPK, p38,
and GSK-3ß activity were performed as described
previously14 using the
following substrates: GST-c-Jun(1–135) for SAPK,
GST-ATF-2(8–94) for p38, myelin basic protein for ERK, and
glycogen synthase peptide-2 (Upstate Biotechnology) for
GSK-3ß.
Cn Phosphatase Assay
Cn phosphatase assays were performed on human left
ventricular free wall samples exactly as described
previously.15
Statistical Analysis
All data are presented as mean±SEM. Differences
between values were evaluated for statistical significance using a
non-paired Student’s t test or
1-way ANOVA followed by Bonferroni’s multiple comparison test when
appropriate. P<0.05 was
considered statistically
significant.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Patient Characteristics
The donor hearts that served as the controls (n=17) were taken from victims of motor vehicle accidents or gunshot wounds. None had suffered cardiac trauma, and none had evidence of underlying cardiac disease. The hypertrophied hearts (n=9) were taken from patients who were initially considered to be donors, with no history or findings of congestive heart failure, but who by echocardiography and/or post-explant examination had marked cardiac hypertrophy, as evidenced by 2D echo wall thicknesses
14 mm and/or heart mass >180
g/m2 for men and 150
g/m2 for women. The heart weights of men
(n=5) ranged from 450 to 808 g (mean, 612±80 g), and those of
women (n=4) ranged from 378 to 587 g (mean, 476±48 g). Underlying
diagnoses were hypertension alone (n=7) and hypertension with CAD
(n=2). For the hearts explanted from patients with heart failure before
cardiac transplantation (n=22), underlying diagnoses were CAD (n=11)
and idiopathic dilated cardiomyopathy (n=11). The
Table
presents patient characteristics in the various groups. We had
insufficient samples to perform all of the assays in all of the hearts.
Therefore, the
Table
presents the hypertrophied and failing hearts that were assayed for Cn
activity and the hypertrophied and failing hearts that were assayed for
kinase activity separately, with their respective control groups. The
groups were well-matched for age and reasonably well-matched for
sex.
|
Cn Activity in Hypertrophied and Failing
Human Hearts
We first examined the activation status of Cn.
There were significant increases in Cn enzymatic activity in both the
hypertrophied (2.7-fold) and failing heart samples (1.7-fold)
(P=0.0005 and
P=0.007, respectively;
Figure 1A), although activity was significantly greater in
hypertrophied hearts compared with failing hearts
(P=0.03;
Figure 1A).
|
We next quantified Cn expression by Western blotting with 4
different CnA antibodies. Both of the pan-CnA antibodies and a
CnAß-specific antibody demonstrated a subtle but significant increase
in Cn protein in both hypertrophied and failing hearts
(Figures 1B
, 1C, and 1D). In contrast, CnA was weakly
detectable and was not changed in abundance
(Figure 1C and 1D). CnA protein was elevated by
1.82±0.36-fold (P<0.05) and
1.5±0.28-fold (P<0.05) in
hypertrophied and failing hearts, respectively. To determine
CnA-specific activity, we normalized enzymatic activity to expression
level in each of the samples
(Figure 1E). These data confirmed that CnA-specific activity
was increased in the hypertrophied but not in the failing hearts.
Collectively, these data indicate that the increase in Cn enzymatic
activity in failing hearts is due largely to increased expression,
whereas in hypertrophied hearts, it is due to both increased expression
and increased specific activity.
ERK, p38, and SAPK Activity in Hypertrophied
and Failing Human Hearts
We next examined the potential association between MAPK
signaling and human hypertrophy and heart failure. The SAPKs were
markedly activated (5.3-fold over control) in hearts from patients with
advanced heart failure. Lesser but significant activation of the ERKs
(3.6-fold) and p38 (2.0-fold) was also found
(Figures 2A, 3A, and 4A). Activation of the 3 MAPK pathways
was evident, irrespective of whether the underlying disease was
ischemia or idiopathic dilated cardiomyopathy (data not
shown).
|
|
|
In the hypertrophied heart samples, none of the MAPKs were
activated
(Figures 2A, 3A, and 4A). Western blotting confirmed the
equivalent expression of each of the kinases in normal, hypertrophied,
and failing heart samples, confirming that increased kinase activity in
the failing hearts was due to an increase in specific activity
(Figures 2B, 2C, 3B, 3C, 4B, and 4C, bottom panels). We
further confirmed the increase in MAPK activity by Western blotting
with dual phospho-specific antibodies, which demonstrated increased
phosphorylation of SAPK, ERK, and p38 in the samples from failing but
not hypertrophied hearts
(Figures 2B, 2C, 3B, 3C, 4B, and 4C, top panels). Of note,
only the p54 isoform of SAPK, and not the p46 isoform, seemed to be
activated in the failing hearts, suggesting differential regulation of
these isoforms. Taken together, these data indicate that all 3 MAPK
signaling pathways are activated in the failing myocardium but not in
the hypertrophied heart.
Akt and GSK-3ß Activity in Hypertrophied and
Failing Human Hearts
Akt is activated as a downstream consequence of growth
factor signaling through phosphoinositide-3 kinases, and activation of
Akt has been associated with protection from apoptosis in cardiac
myocytes.9 Because
progressive myocyte apoptosis may contribute to heart failure, we
examined the activation status of Akt by Western blotting with a
phospho-specific antibody. We observed a marked increase in Akt
phosphorylation in failing hearts compared with control hearts, but
absolute protein levels were invariant
(Figure 5C). In hypertrophied hearts, Akt phosphorylation was
not significantly increased
(Figure 5D).
|
GSK-3 is a kinase with profound effects on fetal development
and tumorigenesis. The activity of GSK-3 is negatively regulated by Akt
in many cell types, and inhibiting GSK-3 seems to be critical to the
antiapoptotic effects of
Akt11 and to the
hypertrophic response of
cardiomyocytes.13 Consistent
with the activation of Akt, we observed a significant inhibition of
GSK-3ß activity in failing hearts but no inhibition in hypertrophied
hearts
(Figure 5A and 5B). The 31% inhibition of GSK-3ß in the
failing hearts was quite marked considering that IGF-1, a potent
inhibitor of GSK-3, produced 
40% inhibition in cardiomyocytes in
culture.13 These data
indicate that the PI3K/Akt signaling pathway is not activated in
hypertrophied hearts but is significantly activated in failing
hearts.
We next examined possible mechanisms of Akt activation in
human heart failure. Three pro-survival factors that are also
implicated in the hypertrophic growth of the heart and that signal via
the PI3-kinase/Akt pathway are IGF-1 (which acts through its cognate
receptor), neuregulin-1 (which acts through ErbB receptors), and the
interleukin-6 family member cardiotrophin-1 (which acts through gp130,
a shared signaling subunit of interleukin-6 family
receptors).16 To determine
the activation state of the receptors for IGF-1 and neuregulin, we
immunoprecipitated lysates from normal donor hearts and failing hearts
with antibodies to IGF-1R and to the ErbB2 receptor and then
immunoblotted them with an antibody to phosphotyrosine. These studies
demonstrated that the IGF-1 receptor in failing hearts is in a more
activated state than it is in normal hearts, as based on the
significantly increased content of phosphotyrosine
(Figure 6A). In contrast, the activation state of the ErbB2
receptor seems to be decreased in failing hearts
(Figure 6B). We could detect no consistent trend in gp130
signaling in the failing hearts on the basis of immunoblotting for
phospho-STAT3, one of the major downstream targets of gp130 (data not
shown).16 Although many
agonists that are increased in heart failure, including angiotensin II
and endothelin-1, can activate Akt, our data suggest that the increased
activation of the IGF-1 receptor may in part account for the activation
of Akt we observed in advanced heart failure. In contrast, another
major prosurvival pathway (signaling via ErbB2) seems to be
downregulated, and this may be expected to have an adverse effect on
cardiomyocyte survival in the failing
heart.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Little is known about the intracellular mechanisms that precede human heart failure or the mechanisms that underlie progressive deterioration of function. To date, no studies have reported CnA enzymatic activity in failing human hearts, none have examined the activity of >1 group of signaling factors in failing hearts, and the activation state of these pathways in hypertrophied human hearts is not known. We postulated that defining an activity profile in both hypertrophied and failing human hearts might provide clues to the mechanisms driving the transition from hypertrophy to heart failure and the progression of heart failure.
Profile of Activity of the Hypertrophied
Heart
Our data show striking differences in the activity of
signaling pathways between patients with compensated hypertrophy and
those with advanced heart failure. Most notably, the Cn pathway seems
to be the dominant pathway activated in compensated hypertrophy, and
the increased activity is due both to increased expression and to an
increase in specific activity. In contrast, we could detect no
significant activation of any of the MAPK pathways or the Akt/GSK-3
pathway.
Cn is a calcium-calmodulin–activated intracellular phosphatase that was recently shown to induce cardiac hypertrophy in transgenic mice.1 17 There has, however, been ongoing debate concerning the role of Cn in the development of cardiac hypertrophy in response to the physiologically relevant stress of pressure overload.1 2 Although the exact role of Cn in the development of acute pressure-overload hypertrophy in experimental animal models remains somewhat unclear, our data suggest that Cn likely does play a role in the maintenance of the hypertrophic phenotype in humans. In contrast, the other signaling pathways we examined do not seem to modulate this phase of the disease. Thus, although various of the MAPK pathways have been clearly implicated in the development of cardiac hypertrophy in experimental animals, it seems from our data that in the compensated phase of chronic hypertrophy, these pathways may not be appropriate targets for therapeutic intervention. In contrast, Cn may be a target for intervention.
Profile of Activity of the Failing
Heart
The profile of activity of the various signaling
pathways in the failing heart is much more complex than that of the
hypertrophied heart. We found significant activation of Cn (although
not as marked as in the hypertrophic hearts), marked activation of the
SAPKs with lesser activation of the ERKs and p38, and activation of Akt
with the corresponding inhibition of its downstream target
GSK-3ß.
Cn enzymatic activity is increased 1.7-fold in the hearts of
patients with failure. Previously, we reported that the content of Cn
complexed with calmodulin was increased in failing human hearts,
inferring activation.5
Although this assay suggests that Cn is in an activated complex with
calmodulin, it is uncertain if this accurately reflects enzymatic
activity. To address this issue, we directly measured enzymatic
phosphatase activity. The enzymatic assay supports our previous
conclusions in the failing heart. The data also show that Cn protein
content is upregulated in failing hearts, albeit to a lesser extent
than that in hypertrophied hearts, and that the increased activity is
largely due to this increased expression and not to an increase in
specific activity. In contrast, Tsao et
al6 reported decreases in Cn
protein in failing human hearts using 1 vendor source of antibody but
increases in Cn using a different antibody. Using the same 2 pan-CnA
antibodies, we identified a significant increase in Cn protein content
in failing hearts. We also demonstrated a specific increase in CnAß
protein, whereas CnA was only weakly detected in the adult human
heart. Tsao et al6 reported
decreased levels of CnAß mRNA in failing hearts, but the probe they
used recognizes only CnAß2, a minor splice form of Cn expressed at
low levels in the heart. We think that our Western blotting data, taken
together with our activity data, confirm that Cn activity and protein
levels are upregulated in heart failure.
For the other signaling pathways, Cook et al4 reported that SAPK and p38 phosphorylation were increased in human hearts with failure secondary to advanced CAD. We confirmed the activation of SAPK and p38 in failing hearts due to CAD and extended our observations to include patients with idiopathic dilated cardiomyopathy. Our results indicate that each of the 3 branches of the MAPK signaling pathway are activated in advanced heart failure, irrespective of the cause of the failure.
Activation of the MAPKs in the failing heart may be due to several factors, including increased wall stress (which leads to myocyte stretching), increased levels of neurohormonal mediators of heart failure, or increased circulating cytokines. The activated MAPKs may play various roles in the failing heart, but given the demonstrated role of the SAPKs and, possibly, p38 in the hypertrophic response in vivo,14 16 it seems likely that their activation would help normalize wall stress via hypertrophy were it not for the very limited ability of the failing heart to respond.
This report contains the first data associating Akt activation with heart failure. The activation of Akt and consequent inhibition of GSK-3 may protect cells from apoptosis.8 11 Therefore, the demonstration of activation of Akt in the hearts of patients with advanced failure is somewhat surprising, because studies have documented apoptosis in these hearts and have postulated that apoptosis may play a role in the progression of heart failure.7 These data raise questions regarding the roles Akt may play in these hearts. Because Akt can block cell death even after cytochrome c has been released,8 our data raise the possibility that the widespread aborted apoptosis observed by Narula et al7 in the failing heart may be due to Akt activation. In addition, the activation of Akt and the subsequent inhibition of GSK-3 transduce prohypertrophic signals.13 Finally, Akt regulates GLUT4 translocation, which causes enhanced glucose uptake, and Akt activation may serve to improve energy utilization.18
Inhibition of GSK-3ß may also have multiple effects in the failing heart. In addition to protecting from apoptosis, GSK-3ß phosphorylates the nuclear factors of activated T cells (NF-ATs), which are transcription factors thought to play a role in the hypertrophic response of the heart and in skeletal muscle.13 17 19 This phosphorylation excludes NF-ATs from the nucleus, rendering them inactive. Because Cn dephosphorylates NF-ATs, the activation of Cn and simultaneous inhibition of GSK-3ß should provide a potent stimulus to NF-AT nuclear translocation and activation in the failing heart. In contrast, the persistent activation of the SAPKs, which can inhibit Cn/NF-AT interactions,20 may serve as a check to prevent unrestrained activation of the pathway in the failing heart.
Rezvani and Liew21 recently reported that protein levels (but not mRNA levels) of the transcriptional activator ß-catenin were increased in post mortem samples from the hearts of patients with advanced heart disease. Because GSK-3ß phosphorylates ß-catenin when active, thus targeting it for ubiquitination and degradation, inhibiting GSK-3ß activity in the failing heart may be one mechanism of the observed increase in ß-catenin expression. The demonstration of altered regulation of a bona fide downstream target of GSK-3ß adds additional significance to our findings of the inhibition of GSK-3ß in human heart disease.
Study Limitations
Although the 3 groups of patients were matched
reasonably well for age and sex, the clinical state of the patients
with advanced failure demanded multiple medications and interventions
that neither the control nor hypertrophy groups required. Although it
is possible that these interventions caused the alterations in
signaling in the failing hearts, comparisons within the failure group
showed no trends that would suggest a correlation between any
medication/device and activation of a signaling pathway. For the
pathways, activation was consistent across the entire failure
group.
Finally, this study is, by necessity, correlative in nature. However, important insights can still be gained. Our analysis revealed differential regulation of multiple intracellular signaling pathways in the hypertrophied versus the failing hearts, raising the possibility that this differential regulation plays a causal role in the transition from hypertrophy to failure. The data also allow us to form hypotheses concerning signaling pathways that may and may not be appropriate targets for novel therapeutic strategies designed to regress hypertrophy, to influence the transition from compensated to decompensated phenotypes, and to alter the inexorable progression of heart failure. These hypotheses can be readily tested in experimental models of hypertrophy and heart failure.
|
Acknowledgments |
|---|
Supported by National Institutes of Health grants HL69562, HL62927, and HL52318 (to J.D.M.); HL50361 and HL57623 (to R.H.); and DK50282 and HL61688 (to T.F.), as well as a Pew Scholars award and an American Heart Affiliate grant-in-aid (to J.D.M.). T.F. is an Established Investigator of the American HeartAssociation. H.L. was supported by National Institues of Health training grant T32ES07051.
|
Footnotes |
|---|
The first 2 authors contributed equally to this work.
Received July 18, 2000; revision received September 29, 2000; accepted October 4, 2000.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
-
Olson EN,
Molkentin JD. Prevention of cardiac hypertrophy by calcineurin
inhibition: hope or hype? Circ
Res. 1999;84:623–632.
[Free Full Text]
-
Sugden PH.
Signaling in myocardial hypertrophy: life after calcineurin?
Circ Res. 1999;84:633–646.
[Free Full Text]
-
Bowling N, Walsh
RA, Song G, et al. Increased protein kinase C activity and
expression of Ca2+ sensitive isoforms in the
failing human heart.
Circulation. 1999;99:384–391.
[Abstract/Free Full Text]
-
Cook SA, Sugden PH,
Clerk A. Activation of c-Jun N-terminal kinases and
p38-mitogen-activated protein kinases in human heart failure secondary
to ischaemic heart disease. J Mol Cell
Cardiol. 1999;31:1429–1431.[Medline]
[Order article via Infotrieve]
-
Lim HW, Molkentin
JD. Calcineurin and human heart failure.
Nat Med. 1999;5:246–247.[Medline]
[Order article via Infotrieve]
-
Tsao L, Neville C,
Musaro A, et al. Revisiting calcineurin and human heart failure.
Nat Med. 2000;6:2–3.[Medline]
[Order article via Infotrieve]
-
Narula J, Pandey P,
Arbustini E, et al. Apoptosis in heart failure: release of cytochrome c
from mitochondria and activation of caspase-3 in human cardiomyopathy.
Proc Natl Acad Sci
U S A. 1999;96:8144–8149.
[Abstract/Free Full Text]
-
Datta SR, Brunet A,
Greenberg ME. Cellular survival: a play in three Akts.
Genes Dev. 1999;13:2906–2927.
-
Matsui T, Li L, del
Monte F, et al. Adenoviral gene transfer of activated
phosphatidylinositol 3'-kinase and Akt inhibits apoptosis of hypoxic
cardiomyocytes in vitro.
Circulation. 1999;100:2373–2379.
[Abstract/Free Full Text]
-
Wang HG, Pathan
N, Ethell IM, et al. Ca2+-induced apoptosis
through calcineurin dephosphorylation of BAD.
Science. 1999;284:339–343.
[Abstract/Free Full Text]
-
Pap M, Cooper G.
Role of glycogen synthase kinase-3 in the phosphatidylinositol
3-kinase/Akt cell survival pathway. J
Biol Chem. 1998;273:19929–19932.
[Abstract/Free Full Text]
-
Kyriakis JM,
Avruch J. Protein kinase cascades activated by stress and inflammatory
cytokines. Bioessays. 1996;18:567–577.[Medline]
[Order article via Infotrieve]
-
Haq S, Choukroun
G, Kang ZB, et al. Glycogen synthase kinase-3ß is a negative
regulator of cardiomyocyte hypertrophy.
J Cell Biol.2000;151:117–129.
-
Choukroun G,
Hajjar R, Fry S, et al. Regulation of cardiac hypertrophy in vivo by
the stress-activated protein kinases/c-Jun
NH2-terminal kinases.
J Clin Invest. 1999;104:391–398.[Medline]
[Order article via Infotrieve]
-
Lim HW, DeWindt
LJ, Steinberg L, et al. Calcineurin expression, activation, and
function in cardiac pressure overload hypertrophy.
Circulation. 2000;101:2431–2437.
[Abstract/Free Full Text]
-
Chien KR. Stress
pathways and heart failure.
Cell. 1999;98:555–558.[Medline]
[Order article via Infotrieve]
-
Molkentin JD, Lu
JR, Antos CL, et al. A calcineurin-dependent transcriptional pathway
for cardiac hypertrophy. Cell. 1998;93:215–228.[Medline]
[Order article via Infotrieve]
-
Wang Q, Somwar R,
Bilan PJ, et al. Protein kinase B/Akt participates in GLUT4
translocation by insulin in L6 myocytes.
Mol Cell Biol. 1999;19:4008–4018.
[Abstract/Free Full Text]
-
Musaro A,
McCullagh KJA, Naya FJ, et al. IGF-1 induces skeletal myocyte
hypertrophy through calcineurin in association with GATA-2 and NF-ATc1.
Nature. 1999;400:581–585.[Medline]
[Order article via Infotrieve]
-
Chow CW, Dong C,
Flavell RA, et al. c-Jun NH2-terminal kinase inhibits targeting of the
protein phosphatase calcineurin to NFATc1.
Mol Cell Biol. 2000;20:5227–5234.
[Abstract/Free Full Text]
-
Rezvani M, Liew
CC. Role of the adenomatous polyposis coli gene product in human
cardiac development and disease. J
Biol Chem. 2000;275:18470–18475.
[Abstract/Free Full Text]
This article has been cited by other articles:
 |
|
 |
|
  R. Ventura-Clapier, A. Garnier, and V. Veksler Transcriptional control of mitochondrial biogenesis: the central role of PGC-1{alpha} Cardiovasc Res, July 15, 2008; 79(2): 208 - 217. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Houser and J. D. Molkentin Does Contractile Ca2+ Control Calcineurin-NFAT Signaling and Pathological Hypertrophy in Cardiac Myocytes? Sci. Signal., June 24, 2008; 1(25): pe31 - pe31. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Y. Oudit, Z. Kassiri, J. Zhou, Q. C. Liu, P. P. Liu, P. H. Backx, F. Dawood, M. A. Crackower, J. W. Scholey, and J. M. Penninger Loss of PTEN attenuates the development of pathological hypertrophy and heart failure in response to biomechanical stress Cardiovasc Res, June 1, 2008; 78(3): 505 - 514. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Hill and E. N. Olson Cardiac Plasticity N. Engl. J. Med., March 27, 2008; 358(13): 1370 - 1380. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Beeri, C. Yosefy, J. L. Guerrero, F. Nesta, S. Abedat, M. Chaput, F. del Monte, M. D. Handschumacher, R. Stroud, S. Sullivan, et al. Mitral regurgitation augments post-myocardial infarction remodeling failure of hypertrophic compensation. J. Am. Coll. Cardiol., January 29, 2008; 51(4): 476 - 486. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Liao and T. Force Not All Hypertrophy Is Created Equal Circ. Res., November 26, 2007; 101(11): 1069 - 1072. [Full Text] [PDF]
|
|
|
|
|
|
S. Hirotani, P. Zhai, H. Tomita, J. Galeotti, J. P. Marquez, S. Gao, C. Hong, A. Yatani, J. Avila, and J. Sadoshima Inhibition of Glycogen Synthase Kinase 3{beta} During Heart Failure Is Protective Circ. Res., November 26, 2007; 101(11): 1164 - 1174. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z.-Q. Jin, J. Zhang, Y. Huang, H. E. Hoover, D. A. Vessey, and J. S. Karliner A sphingosine kinase 1 mutation sensitizes the myocardium to ischemia/reperfusion injury Cardiovasc Res, October 1, 2007; 76(1): 41 - 50. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Beeri, C. Yosefy, J. L. Guerrero, S. Abedat, M. D. Handschumacher, R. E. Stroud, S. Sullivan, M. Chaput, D. Gilon, G. J. Vlahakes, et al. Early Repair of Moderate Ischemic Mitral Regurgitation Reverses Left Ventricular Remodeling: A Functional and Molecular Study Circulation, September 11, 2007; 116(11_suppl): I-288 - I-293. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Muchir, P. Pavlidis, G. Bonne, Y. K. Hayashi, and H. J. Worman Activation of MAPK in hearts of EMD null mice: similarities between mouse models of X-linked and autosomal dominant Emery Dreifuss muscular dystrophy Hum. Mol. Genet., August 1, 2007; 16(15): 1884 - 1895. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. E. Hannigan, J. G. Coles, and S. Dedhar Integrin-Linked Kinase at the Heart of Cardiac Contractility, Repair, and Disease Circ. Res., May 25, 2007; 100(10): 1408 - 1414. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. A.M. van de Schans, S. W.M. van den Borne, A. E. Strzelecka, B. J.A. Janssen, J. L.J. van der Velden, R. C.J. Langen, A. Wynshaw-Boris, J. F.M. Smits, and W. M. Blankesteijn Interruption of Wnt Signaling Attenuates the Onset of Pressure Overload-Induced Cardiac Hypertrophy Hypertension, March 1, 2007; 49(3): 473 - 480. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Lu, P. W. M. Fedak, X. Dai, C. Du, Y.-Q. Zhou, M. Henkelman, P. S. Mongroo, A. Lau, H. Yamabi, A. Hinek, et al. Integrin-Linked Kinase Expression Is Elevated in Human Cardiac Hypertrophy and Induces Hypertrophy in Transgenic Mice Circulation, November 21, 2006; 114(21): 2271 - 2279. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Schiekofer, I. Shiojima, K. Sato, G. Galasso, Y. Oshima, and K. Walsh Microarray analysis of Akt1 activation in transgenic mouse hearts reveals transcript expression profiles associated with compensatory hypertrophy and failure Physiol Genomics, October 11, 2006; 27(2): 156 - 170. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. W. Kong, W. T. Pu, and P. J. Park A multivariate approach for integrating genome-wide expression data and biological knowledge Bioinformatics, October 1, 2006; 22(19): 2373 - 2380. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Javadov, D. M. Purdham, A. Zeidan, and M. Karmazyn NHE-1 inhibition improves cardiac mitochondrial function through regulation of mitochondrial biogenesis during postinfarction remodeling Am J Physiol Heart Circ Physiol, October 1, 2006; 291(4): H1722 - H1730. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Kerkela and T. Force p38 Mitogen-Activated Protein Kinase: A Future Target for Heart Failure Therapy? J. Am. Coll. Cardiol., August 1, 2006; 48(3): 556 - 558. [Full Text] [PDF]
|
|
|
|
 |
|
 F. A. Babiker, D. Lips, R. Meyer, E. Delvaux, P. Zandberg, B. Janssen, G. van Eys, C. Grohe, and P. A. Doevendans Estrogen Receptor {beta} Protects the Murine Heart Against Left Ventricular Hypertrophy Arterioscler. Thromb. Vasc. Biol., July 1, 2006; 26(7): 1524 - 1530. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Lister, D. J. Autelitano, A. Jenkins, R. D. Hannan, and K. E. Sheppard Cross talk between corticosteroids and alpha-adrenergic signalling augments cardiomyocyte hypertrophy: A possible role for SGK1 Cardiovasc Res, June 1, 2006; 70(3): 555 - 565. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Walsh Akt Signaling and Growth of the Heart Circulation, May 2, 2006; 113(17): 2032 - 2034. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Matsui, T. Nagoshi, E.-G. Hong, I. Luptak, K. Hartil, L. Li, N. Gorovits, M. J. Charron, J. K. Kim, R. Tian, et al. Effects of chronic Akt activation on glucose uptake in the heart Am J Physiol Endocrinol Metab, May 1, 2006; 290(5): E789 - E797. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Olson, K. N. Protheroe, J. L. Segar, and T. D. Scholz Mitogen-activated protein kinase activation and regulation in the pressure-loaded fetal ovine heart Am J Physiol Heart Circ Physiol, April 1, 2006; 290(4): H1587 - H1595. [Abstract] [Full Text] [PDF]
|
|
|
|